succinobucol has been researched along with Atherogenesis in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kourounakis, AP; Ladopoulou, E; Matralis, AN | 1 |
| Stocker, R | 1 |
| Inazu, A | 1 |
| Tardif, JC | 1 |
| Cynshi, O; Stocker, R | 1 |
| Preiss, DJ; Sattar, N | 1 |
| Eisert, C; Malinin, A; Ong, S; Serebruany, VL | 1 |
6 review(s) available for succinobucol and Atherogenesis
| Article | Year |
|---|---|
Molecular mechanisms underlying the antiatherosclerotic and antidiabetic effects of probucol, succinobucol, and other probucol analogues.
Topics: Animals; Atherosclerosis; Diabetes Mellitus; Humans; Hypoglycemic Agents; Probucol | 2009 |
[Novel therapy for atherosclerosis and inflammatory vascular disease].
Topics: Acetates; Amides; Apolipoprotein A-I; Atherosclerosis; Benzaldehydes; Blood Proteins; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Drug Design; Esters; Humans; Indoles; Keto Acids; Molecular Targeted Therapy; Oxazolidinones; Oximes; Probucol; Quinazolines; Quinazolinones; Sulfhydryl Compounds | 2011 |
Antioxidants: the good, the bad and the ugly.
Topics: Angioplasty, Balloon, Coronary; Antioxidants; Atherosclerosis; Coronary Restenosis; Humans; Oxidative Stress; Probucol; Vitamins | 2006 |
Inhibition of lipoprotein lipid oxidation.
Topics: Animals; Antioxidants; Atherosclerosis; Benzofurans; Cardiovascular Diseases; Humans; Lipoproteins, LDL; Malondialdehyde; Oxidation-Reduction; Probucol; Thiobarbituric Acid Reactive Substances | 2005 |
Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis?
Topics: Antioxidants; Atherosclerosis; Endothelium, Vascular; Evidence-Based Medicine; Gene Expression Regulation; Humans; Probucol; Vascular Cell Adhesion Molecule-1 | 2007 |
AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
Topics: Animals; Antioxidants; Atherosclerosis; Blood Platelets; Coronary Artery Disease; Coronary Restenosis; Cytokines; Disease Progression; Humans; Hypolipidemic Agents; Oxidative Stress; Platelet Aggregation Inhibitors; Probucol; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2007 |
1 other study(ies) available for succinobucol and Atherogenesis
| Article | Year |
|---|---|
New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action.
Topics: Animals; Antioxidants; Atherosclerosis; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Farnesyl-Diphosphate Farnesyltransferase; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins, LDL; Male; Mice; Oxidative Stress; Probucol; Rats | 2013 |